Tailoring access to high cost, genetically targeted drugs

Medical Journal of Australia

Volumn 182, Issue 12, 2005, Pages 607-608

  Hall, Wayne D ^a   Ward, Robyn ^b   Liauw, Winston S ^c   Brien, Jo Anne E ^d   Lu, Christine Y ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETANERCEPT; GEFITINIB; IMATINIB; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TRASTUZUMAB;

AUSTRALIA; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EDITORIAL; GENE MUTATION; GENE OVEREXPRESSION; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; LUNG NON SMALL CELL CANCER; PHARMACOGENETICS; PHARMACOGENOMICS; PRESCRIPTION; PRIVACY; PROGNOSIS; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 21644443971     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2005.tb06844.x     Document Type: Editorial

References (6)

1. Shah J. Criteria influencing the clinical uptake of pharmacogenetic strategies. BMJ 2005; 328: 1482-1486.
2. Collins F, Green ED, Guttmacher A, et al. A vision for the future of genomics research. Nature 2003; 422: 835-847.
3. Australian Institute of Health and Welfare. Health expenditure in Australia 2002-03. Health and Welfare Expenditure Series No. 20. Canberra: AIHW, 2004. (AIHW Cat. No. HWE 27.)
4. Sansom L. The subsidy of pharmaceuticals in Australia: processes and challenges. Aust Health Rev 2004; 28: 194-205.
5. Brown L, Walker A, Waters A, et al. Funding of high cost biotechnology and other innovative targeted therapies under the Pharmaceutical Benefits Scheme (NATSEM Position Paper). Canberra: National Centre for Social and Economic Modeling, 2002. Available at: http://www.natsem.canberra.edu.au/publications/papers/otherpubs/pbs/ pbs_and_highcostdrugs.pdf (accessed 23 Mar 2005).
6. Lu C, March L, Sansom L, et al. Access to high cost drugs in Australia - risk sharing scheme may set a new paradigm. BMJ 2004; 329: 415-416.